BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
McKinsey
Novartis
Citi
Farmers Insurance
Fish and Richardson
Johnson and Johnson
Baxter
Cantor Fitzgerald

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,781,448

« Back to Dashboard

Summary for Patent: 7,781,448
Title:Once daily dosage forms of trospium
Abstract:A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (C.sub.min) and maximum (C.sub.max) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.
Inventor(s): Kidane; Argaw (Montgomery Village, MD), Flanner; Henry H. (Montgomery Village, MD), Bhatt; Padmanabh (Rockville, MD), Raoufinia; Arash (McLean, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:11/889,962
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 7,781,448

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,781,448

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,410,978 Once daily dosage forms of trospium ➤ Subscribe
7,759,359 Method of treating bladder dysfunction with once-a-day trospium salt formulation ➤ Subscribe
7,781,449 Trospium chloride treatment method ➤ Subscribe
7,763,635 Once daily dosage forms of trospium ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,781,448

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 493981 ➤ Subscribe
Australia 2004289223 ➤ Subscribe
Canada 2537103 ➤ Subscribe
Germany 602004030931 ➤ Subscribe
Denmark 2210605 ➤ Subscribe
European Patent Office 1680110 ➤ Subscribe
European Patent Office 2210605 ➤ Subscribe
Spain 2359375 ➤ Subscribe
Hong Kong 1088547 ➤ Subscribe
Japan 2007510656 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Deloitte
Cerilliant
Farmers Insurance
Fish and Richardson
AstraZeneca
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot